Navigation Links
Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2007
Date:3/24/2008

issions were 9,913 and net revenue per patient day was $1,410. This compares to 235,520 days, 9,546 admissions and net revenue per patient day of $1,366 for the same quarter, prior year. For the hospitals opened or acquired as of January 1, 2006 and operated by Select throughout both periods, patient days in the fourth quarter of 2007 were 233,761 and admissions were 9,448, compared to 219,162 days and 8,940 admissions in the same quarter, prior year. Adjusted EBITDA for the segment decreased 25.0% to $48.8 million compared to $65.1 million for the same quarter, prior year. The Adjusted EBITDA margin for the segment was 13.8% for the fourth quarter of 2007, compared to 19.8% for the same quarter, prior year. The Adjusted EBITDA margin for the hospitals opened or acquired as of January 1, 2006 and operated by Select throughout both periods was 16.1% for the fourth quarter of 2007, compared to 21.4% for the same quarter, prior year.

For the year ended December 31, 2007, net operating revenues for all of Select's hospitals increased 0.6% to $1,386.4 million compared to $1,378.5 million for the prior year. Total patient days for the year ended December 31, 2007 were 987,624, admissions were 40,008 and net revenue per patient day was $1,378. This compares to 969,590 days, 39,668 admissions and net revenue per patient day of $1,392 for the prior year. For the hospitals opened or acquired as of January 1, 2006 and operated by Select throughout both periods, patient days for the year ended December 31, 2007 were 927,405 and admissions were 37,710, compared to 892,130 days and 36,721 admissions in the prior year. Adjusted EBITDA for the segment for the year ended December 31, 2007 decreased 23.3% to $217.2 million compared to $283.3 million for the prior year. The Adjusted EBITDA margin for the segment for the year ended December 31, 2007 was 15.7%, compared to 20.5% for the prior year. The Adjusted EBITDA margin for the hospitals opened or acquired as of January 1, 2
'/>"/>

SOURCE Select Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications
2. Wheelchair Professionals Selects Authentidates Inscrybe Healthcare Platform to Streamline Mobility Order Processing
3. Researchers develop a method to select eggs with the best chance of leading to successful pregnancy
4. Hawaiis Premier Physician Management Company, TeamPraxis, Selects Allscripts Electronic Health Record for Statewide Deployment
5. Georgetown U student selected for prestigious Bouchet Society
6. Antares Management Solutions Selects Hyland Softwares OnBase
7. Vendormate Again Selected as Top 40 Georgia Innovative Technology Company
8. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
9. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
10. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
11. Civista Health Inc. Selects Phoenix Health Systems for Information Technology Outsourcing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...to a novel technique to combat cancer, study says,... -- Belgian researchers have discovered that some ...food, and this might lead to new treatments that s...oliferate, all cells in the body need to produce e...process that requires oxygen. Compared with normal...
(Date:11/21/2008)...o Vigorously Protect Investment And Restore Shareh...wire-USNewswire/ -- Dr. Stephen Joffe, Craig Joffe...r Schedule 13D with the U.S. Securities and Exchan...isclosing ownership of 11.4% of LCA-Vision, Inc. (...d-site laser vision correction centers in 33 state...
(Date:11/21/2008)...Newswire-FirstCall/ -- Barr Pharmaceuticals, Inc. ...rs overwhelmingly approved the proposals submitted...va Pharmaceuticals Industries Ltd. (Nasdaq: TEVA...rwhelming support of the transaction by the Barr s...n and CEO. "We are pleased with the progress that ...
(Date:11/21/2008).../ -- In a statewide survey, 33 physicians credenti...y at Presbyterian Hospital of Dallas were honored ... Super Doctors ." , , Each year, the publis... Media, Inc. to survey more than 38,000 medical pr...you needed medical care, which doctor would you ch...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...ders of national embryonic stem cell banks in the ...y to work together to promote //research, create i...bute each other’s cells. The officials told repor...eginning of a long partnership between the Nationa...
... Food and Drug Administration (FDA) is warning con...d due to the presence// of Salmonella, a pathogen....ed and analyzed a sample of frozen raw Wild Kitty ...Cats and other pets consuming this food may become...
...ety percent of the people infected with bird flu h...em have died, according// to the latest analysis f...searchers stressed their analysis did not suggest ... there are several theories on why the H5N1 virus ...
...artificial nose could be a real benefit at times: ...plosives or drugs//, for instance. Researchers a...d the Max Planck Institute of Biochemistry recentl...integrating membrane proteins into artificial stru...
Other Medicine News:Health News:U.S., U.K. Stem Cell Banks to Team Up 2Health News:Consumers Warned of Using Cat Food Due to Salmonella Contamination 2Health News:Max Planck Researchers Incorporate Odorant Receptors into Artificial Membranes 2
(Date:11/20/2008)...0 Duska Therapeutics,I...hat it has submitted its,pivotal Phase 3 ATPace c...,Protocol Assessment (SPA) procedure with the U.S....ject to securing an agreement with the FDA, Duska ...-blind, placebo-controlled and randomized Phase 3,...
(Date:11/20/2008)...swire/ -- Clinical data from a prospective,regist...mposium shows DVT,treatment with the Trellis(R) P...Inc. (Santa Clara, CA) successfully breaks up the ..., This technique, called isolated pharmacom...quickly and safely than current catheter-directed ...
(Date:11/20/2008)...mber 20 The Scandinavian-based dru...ed results of studies on its,lead antimicrobial c..., DC,the studies showed that the novel lytic pep...ct, significantly better towards killing Staphyloc...eted gold standard drugs. In,addition to this it ...
(Date:11/19/2008)...ov. 19 Amgen,(Nasdaq: ...y, a subsidiary of,Takeda Pharmaceutical Company ...ent in the Phase 3 MONET1 trial evaluating motesan...arboplatin for the first-line treatment of,advanc...porarily suspended,following a planned safety dat...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7NMR on a chip features NIST magnetic mini sensor 12295 1NMR on a chip features NIST magnetic mini sensor 12295 2Milady U Provides Continuing Education to Salon and Spa Professionals 12291 1Milady U Provides Continuing Education to Salon and Spa Professionals 12291 2Purdue lab works to improve conditions at indoor swimming pools 12287 1Purdue lab works to improve conditions at indoor swimming pools 12287 2Purdue lab works to improve conditions at indoor swimming pools 12287 3Purdue lab works to improve conditions at indoor swimming pools 12287 4XTENT Announces 2007 Financial Results 12282 1XTENT Announces 2007 Financial Results 12282 2XTENT Announces 2007 Financial Results 12282 3XTENT Announces 2007 Financial Results 12282 4XTENT Announces 2007 Financial Results 12282 5XTENT Announces 2007 Financial Results 12282 6
... Breakthrough Will Aid in Developing Therapies to ... EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- ...development company, announced,today the first met...issues in animals through the pathway known as rev...known mechanism by which excess,cholesterol can be...
...taly--(BUSINESS WIRE)--May 14, 2007 - Acceleron Ph... therapeutics for the,treatment of musculoskeletal...ounced results of a preclinical study with,ACE-031...increase,muscle mass and strength in normal mice a... inhibits negative regulators of muscle,to increas...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
...rovider of Telemedicine monitoring and diagnostic ...mitment to patients and prescribing physicians. It...esting devices that provide enhanced diagnostic an...hone lines. TransMedEx's product line includes the...
... a new, integrated technology and service--mobile,...eat-by-heartbeat, ECG monitoring, analysis and res...nitially focused on helping physicians diagnose an...ssence in diagnosing and treating arrhythmia. Dela...
The Solo microplate incubator is an extremely compact and portable unit for incubating a single microplate up to 50C. ,Solo HT (high temperature) incubates applications requiring higher temperatures
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -
Medicine Products: